Stay updated on Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The new screenshot shows the same ClinicalTrials.gov study record with no changes to core information such as title, sponsor, locations, eligibility criteria, or outcomes; only minor UI and formatting adjustments are visible. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2025-11-03T18:36:50.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    37 days ago
    Change Detected
    Summary
    - Updated the page to include a government-operating-status notice and a new version tag (v3.2.0), replacing the old v3.1.0.
    Difference
    4%
    Check dated 2025-10-06T04:31:14.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    Update: version bumped to v3.1.0 and new contact details added (oncosohn@yuhs.ac) with a corresponding informational identifier; previous version v3.0.2 is removed.
    Difference
    0.1%
    Check dated 2025-09-29T01:26:14.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    Updated page revision from v3.0.1 to v3.0.2 and removed the 'Back to Top' link. No other core content or critical data changed.
    Difference
    0.2%
    Check dated 2025-09-14T18:51:42.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.
    Difference
    0.2%
    Check dated 2025-09-07T13:29:05.000Z thumbnail image
  8. Check
    72 days ago
    Change Detected
    Summary
    The web page has updated its facility name and location details, specifically emphasizing Seoul, South Korea, and the inclusion of 'Skin and Connective Tissue Diseases' and 'pembrolizumab' as key topics.
    Difference
    2%
    Check dated 2025-08-31T11:27:52.000Z thumbnail image

Stay in the know with updates to Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial page.